Explore. Learn. Join the conversation.

Working Group on New TB Drugs

Stop TB Partnership

Kick TB Campaign Expands to Brazil

soccerballFront-300x290

The Kick TB Campaign is a unique project that uses the World’s most popular sport to educate and engage young people in the effort to stop the spread of tuberculosis. First inaugurated in South Africa during the 2010 World Cup, Kick TB has expanded to Brazil, the host country of the 2014 World Cup.

TB R&D Update: Podcast Interview with Dr. Iwao Ojima

Dr. Iwao Ojima

Dr. Iwao Ojima is a Distinguished Professor and Director of the Institute of Chemical Biology and Drug Discovery at Stony Brook University. In this interview, Dr. Ojima discusses the work his lab has been doing on tri-substituted benzimidazole compounds that inhibit TB growth.

Delamanid approved for use in the European Union

otsuka

The European Commission has approved delaminid (Deltyba) for use in patients suffering from MDR-TB.

TB Alliance launches landmark Phase 3 clinical trial aimed at shortening duration of TB treatment

TBAlliance

TB Alliance announces STAND, a Phase 3 Clinical Trial aimed at shortening the duration of treatment for drug-sensitive and MDR-TB.

TB R&D Update: Tuberculosis drug, SQ109, targets multiple enzymes and could treat other diseases while preventing resistance

SQ109

The drug SQ109, developed by Sequella for the treatment of tuberculosis, blocks key biochemical pathways in bacteria, fungi, and parasites. Its range and ability to inhibit multiple targets, makes SQ109 an attractive broad-based antimicrobial compound that also reduces the likelihood of resistance developing in bugs.

27 Mar 2014
by Working Group

Posted in Announcements, TB News, TB Pediatrics, Uncategorized

TB Alliance makes series of announcements regarding new initiatives to combat childhood TB

TBAlliance

TB Alliance, an international non-profit whose mission is to develop better and more affordable drugs against tuberculosis, made three announcements on World TB Day demonstrating their commitment to combating childhood TB.

TB R&D Update: Researchers at EPFL create organization to help bring promising new antibiotic, ‘PBTZ169’, to market

PBTZ169

Researchers at EPFL and the Bach Institute in Moscow have discovered an antibiotic effective against sensitive and MDR-tuberculosis. With support from EPFL, the researchers have created Innovative Medicines for Tuberculosis (iM4TB), an organization to help usher the new antibiotic to market.

Sirturo (bedaquiline) approved for conditional use in European Union to treat MDR-TB in adults

Sirturo

The European Medicines Agency has recently approved Sirturo for conditional use in the European Union. A link to the press release is included.

TB R&D Update: Semisynthetic antibiotic effective against sensitive and drug resistant tuberculosis in vitro

St Judes

This week we highlight a study by Richard E. Lee et al showing that semisynthetic antibiotic, spectinamides, is effective against drug sensitive and resistant tuberculosis. Additional links related to this study and general TB R&D are included.

26 Nov 2013

EMA Reverses Opinion on Delamanid for MDR-TB

otsuka

A European Union panel has recommended regulatory approval of a tuberculosis drug that would become only the second major new antibiotic against the deadly disease in more than 40 years.